ALNYLAM PHARMACEUTICALS INC (ALNY) Fundamental Analysis & Valuation

NASDAQ:ALNY • US02043Q1076

322.38 USD
-1.21 (-0.37%)
At close: Mar 10, 2026
321.29 USD
-1.09 (-0.34%)
Pre-Market: 3/11/2026, 8:42:54 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ALNY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

Taking everything into account, ALNY scores 6 out of 10 in our fundamental rating. ALNY was compared to 519 industry peers in the Biotechnology industry. ALNY has only an average score on both its financial health and profitability. ALNY is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make ALNY a good candidate for growth investing.


Dividend Valuation Growth Profitability Health

6

1. ALNY Profitability Analysis

1.1 Basic Checks

  • In the past year ALNY was profitable.
  • ALNY had a positive operating cash flow in the past year.
  • In the past 5 years ALNY reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: ALNY reported negative operating cash flow in multiple years.
ALNY Yearly Net Income VS EBIT VS OCF VS FCFALNY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B

1.2 Ratios

  • ALNY has a better Return On Assets (6.32%) than 92.29% of its industry peers.
  • ALNY has a Return On Equity of 39.76%. This is amongst the best in the industry. ALNY outperforms 98.27% of its industry peers.
  • With an excellent Return On Invested Capital value of 11.32%, ALNY belongs to the best of the industry, outperforming 94.80% of the companies in the same industry.
Industry RankSector Rank
ROA 6.32%
ROE 39.76%
ROIC 11.32%
ROA(3y)-3.91%
ROA(5y)-13.41%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALNY Yearly ROA, ROE, ROICALNY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 -400 600

1.3 Margins

  • ALNY has a better Profit Margin (8.45%) than 89.98% of its industry peers.
  • ALNY's Operating Margin of 13.51% is amongst the best of the industry. ALNY outperforms 91.91% of its industry peers.
  • ALNY has a Gross Margin of 81.64%. This is amongst the best in the industry. ALNY outperforms 85.36% of its industry peers.
  • ALNY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 13.51%
PM (TTM) 8.45%
GM 81.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.84%
GM growth 5Y-0.6%
ALNY Yearly Profit, Operating, Gross MarginsALNY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ALNY Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ALNY is creating some value.
  • The number of shares outstanding for ALNY has been increased compared to 1 year ago.
  • The number of shares outstanding for ALNY has been increased compared to 5 years ago.
  • Compared to 1 year ago, ALNY has an improved debt to assets ratio.
ALNY Yearly Shares OutstandingALNY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ALNY Yearly Total Debt VS Total AssetsALNY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • ALNY has an Altman-Z score of 5.96. This indicates that ALNY is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of ALNY (5.96) is better than 73.80% of its industry peers.
  • The Debt to FCF ratio of ALNY is 5.80, which is a neutral value as it means it would take ALNY, 5.80 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 5.80, ALNY belongs to the best of the industry, outperforming 91.71% of the companies in the same industry.
  • A Debt/Equity ratio of 3.14 is on the high side and indicates that ALNY has dependencies on debt financing.
  • ALNY's Debt to Equity ratio of 3.14 is on the low side compared to the rest of the industry. ALNY is outperformed by 80.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.14
Debt/FCF 5.8
Altman-Z 5.96
ROIC/WACC1.3
WACC8.73%
ALNY Yearly LT Debt VS Equity VS FCFALNY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B

2.3 Liquidity

  • A Current Ratio of 2.76 indicates that ALNY has no problem at all paying its short term obligations.
  • ALNY's Current ratio of 2.76 is on the low side compared to the rest of the industry. ALNY is outperformed by 67.44% of its industry peers.
  • ALNY has a Quick Ratio of 2.71. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.71, ALNY is not doing good in the industry: 65.70% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.76
Quick Ratio 2.71
ALNY Yearly Current Assets VS Current LiabilitesALNY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. ALNY Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 191.24% over the past year.
  • Looking at the last year, ALNY shows a very strong growth in Revenue. The Revenue has grown by 65.19%.
  • Measured over the past years, ALNY shows a very strong growth in Revenue. The Revenue has been growing by 49.77% on average per year.
EPS 1Y (TTM)191.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%226.15%
Revenue 1Y (TTM)65.19%
Revenue growth 3Y52.98%
Revenue growth 5Y49.77%
Sales Q2Q%84.95%

3.2 Future

  • The Earnings Per Share is expected to grow by 64.83% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, ALNY will show a very strong growth in Revenue. The Revenue will grow by 24.60% on average per year.
EPS Next Y276.83%
EPS Next 2Y137.42%
EPS Next 3Y94.79%
EPS Next 5Y64.83%
Revenue Next Year48.11%
Revenue Next 2Y39.75%
Revenue Next 3Y32.08%
Revenue Next 5Y24.6%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALNY Yearly Revenue VS EstimatesALNY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
ALNY Yearly EPS VS EstimatesALNY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

6

4. ALNY Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 162.82 indicates a quite expensive valuation of ALNY.
  • 88.05% of the companies in the same industry are more expensive than ALNY, based on the Price/Earnings ratio.
  • ALNY's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.25.
  • The Price/Forward Earnings ratio is 43.21, which means the current valuation is very expensive for ALNY.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ALNY indicates a rather cheap valuation: ALNY is cheaper than 91.33% of the companies listed in the same industry.
  • ALNY is valuated expensively when we compare the Price/Forward Earnings ratio to 24.39, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 162.82
Fwd PE 43.21
ALNY Price Earnings VS Forward Price EarningsALNY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150

4.2 Price Multiples

  • ALNY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ALNY is cheaper than 90.17% of the companies in the same industry.
  • ALNY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ALNY is cheaper than 91.91% of the companies in the same industry.
Industry RankSector Rank
P/FCF 91.87
EV/EBITDA 74.1
ALNY Per share dataALNY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

  • ALNY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ALNY has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as ALNY's earnings are expected to grow with 94.79% in the coming years.
PEG (NY)0.59
PEG (5Y)N/A
EPS Next 2Y137.42%
EPS Next 3Y94.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALNY Dividend Analysis

5.1 Amount

  • No dividends for ALNY!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALNY Fundamentals: All Metrics, Ratios and Statistics

ALNYLAM PHARMACEUTICALS INC

NASDAQ:ALNY (3/10/2026, 8:05:51 PM)

Premarket: 321.29 -1.09 (-0.34%)

322.38

-1.21 (-0.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)04-29
Inst Owners101.56%
Inst Owner Change-1.68%
Ins Owners0.22%
Ins Owner Change10.84%
Market Cap42.75B
Revenue(TTM)3.71B
Net Income(TTM)313.75M
Analysts80
Price Target462.14 (43.35%)
Short Float %4%
Short Ratio3.27
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)74.34%
Min EPS beat(2)-28.48%
Max EPS beat(2)177.15%
EPS beat(4)3
Avg EPS beat(4)59.12%
Min EPS beat(4)-28.48%
Max EPS beat(4)177.15%
EPS beat(8)6
Avg EPS beat(8)47.92%
EPS beat(12)9
Avg EPS beat(12)45.85%
EPS beat(16)10
Avg EPS beat(16)29.15%
Revenue beat(2)1
Avg Revenue beat(2)8.48%
Min Revenue beat(2)-8.27%
Max Revenue beat(2)25.23%
Revenue beat(4)2
Avg Revenue beat(4)7.97%
Min Revenue beat(4)-8.27%
Max Revenue beat(4)25.23%
Revenue beat(8)4
Avg Revenue beat(8)10.34%
Revenue beat(12)6
Avg Revenue beat(12)13.44%
Revenue beat(16)7
Avg Revenue beat(16)7.94%
PT rev (1m)-4.23%
PT rev (3m)-6.81%
EPS NQ rev (1m)-30.14%
EPS NQ rev (3m)-23.35%
EPS NY rev (1m)11.38%
EPS NY rev (3m)7.22%
Revenue NQ rev (1m)-7.37%
Revenue NQ rev (3m)-5.38%
Revenue NY rev (1m)2.62%
Revenue NY rev (3m)4.3%
Valuation
Industry RankSector Rank
PE 162.82
Fwd PE 43.21
P/S 11.51
P/FCF 91.87
P/OCF 81.58
P/B 54.18
P/tB 54.18
EV/EBITDA 74.1
EPS(TTM)1.98
EY0.61%
EPS(NY)7.46
Fwd EY2.31%
FCF(TTM)3.51
FCFY1.09%
OCF(TTM)3.95
OCFY1.23%
SpS28
BVpS5.95
TBVpS5.95
PEG (NY)0.59
PEG (5Y)N/A
Graham Number16.28
Profitability
Industry RankSector Rank
ROA 6.32%
ROE 39.76%
ROCE 14.33%
ROIC 11.32%
ROICexc 66.99%
ROICexgc 66.99%
OM 13.51%
PM (TTM) 8.45%
GM 81.64%
FCFM 12.53%
ROA(3y)-3.91%
ROA(5y)-13.41%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.84%
GM growth 5Y-0.6%
F-Score6
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 3.14
Debt/FCF 5.8
Debt/EBITDA 4.45
Cap/Depr 105.46%
Cap/Sales 1.58%
Interest Coverage 2.29
Cash Conversion 94.05%
Profit Quality 148.33%
Current Ratio 2.76
Quick Ratio 2.71
Altman-Z 5.96
F-Score6
WACC8.73%
ROIC/WACC1.3
Cap/Depr(3y)93.68%
Cap/Depr(5y)120.71%
Cap/Sales(3y)2.17%
Cap/Sales(5y)4.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)191.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%226.15%
EPS Next Y276.83%
EPS Next 2Y137.42%
EPS Next 3Y94.79%
EPS Next 5Y64.83%
Revenue 1Y (TTM)65.19%
Revenue growth 3Y52.98%
Revenue growth 5Y49.77%
Sales Q2Q%84.95%
Revenue Next Year48.11%
Revenue Next 2Y39.75%
Revenue Next 3Y32.08%
Revenue Next 5Y24.6%
EBIT growth 1Y383.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year126.01%
EBIT Next 3Y65%
EBIT Next 5Y46.92%
FCF growth 1Y1192.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6405.1%
OCF growth 3YN/A
OCF growth 5YN/A

ALNYLAM PHARMACEUTICALS INC / ALNY FAQ

Can you provide the ChartMill fundamental rating for ALNYLAM PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 6 / 10 to ALNY.


What is the valuation status for ALNY stock?

ChartMill assigns a valuation rating of 6 / 10 to ALNYLAM PHARMACEUTICALS INC (ALNY). This can be considered as Fairly Valued.


How profitable is ALNYLAM PHARMACEUTICALS INC (ALNY) stock?

ALNYLAM PHARMACEUTICALS INC (ALNY) has a profitability rating of 6 / 10.


How financially healthy is ALNYLAM PHARMACEUTICALS INC?

The financial health rating of ALNYLAM PHARMACEUTICALS INC (ALNY) is 5 / 10.


What is the earnings growth outlook for ALNYLAM PHARMACEUTICALS INC?

The Earnings per Share (EPS) of ALNYLAM PHARMACEUTICALS INC (ALNY) is expected to grow by 276.83% in the next year.